Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation

Pediatric Transplantation

Volumn 16, Issue 2, 2012, Pages 144-150

  Bordon, Victoria ^a   Padalko, Elizaveta ^a   Benoit, Yves ^a   Dhooge, Catharina ^a   Laureys, Genevieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

allogeneic stem cell transplantation; children; Epstein Barr virus infections

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; FRESENIUS; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; ENCEPHALITIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GASTROENTERITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; INFANT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PNEUMOCYSTOSIS; PNEUMONIA; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; T CELL DEPLETION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; LOGISTIC MODELS; MALE; POSTOPERATIVE COMPLICATIONS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 84857643998     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01634.x     Document Type: Article

References (24)

1. Heslop H,. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005: 260-266.
2. Rikinson AB, Lee SP, Steven NM,. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996: 8: 492-497. (Pubitemid 26280777)
3. Callan MF,. The immune response to Epstein-Barr virus. Microbes Infect 2004: 6: 937-945. (Pubitemid 39061216)
4. Styczynski J, Reusser P, Einsele H, et al., Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009: 43: 757-770.
5. Faye A, Vilmer E,. Post-transplant lymphoproliferative disorder in children: Incidence, prognosis and treatment options. Paediatr Drugs 2005: 7: 55-65. (Pubitemid 40444229)
6. Curtis R, Travis L, Rowlings P, Banks PM,. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999: 94: 2208-2216. (Pubitemid 29467666)
7. Webber SA, Naftel DC, Fricker FJ, et al., Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006: 367: 233-239. (Pubitemid 43107668)
8. Fernandez MC, Bes D, De Davila M, et al., Post-transplant lymphoproliferative disorder after pediatric liver transplantation: Characteristics and outcome. Pediatr Transplant 2009: 13: 307-310.
9. Bingler MA, Feingold B, Miller SA, et al., Chronic high Epstein-Barr viral load state and risk for late onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008: 8: 442-445.
10. Van Esser JWJ, Van Der Holt B, Meijer E, et al., Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV lymphoproliferative disease following T-cell-depleted SCT. Blood 2001: 98: 972-988.
11. Wagner HJ, Cheng YC, Huls MH, et al., Prompt versus pre-emptive intervention for EBV lymphoproliferative disease. Blood 2004: 103: 3979-3981. (Pubitemid 38596322)
12. Greefield HM, Gharib MI, Turner AJ, et al., The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant recipients: Can it successful predict outcome and guide intervensions? Pediatr Blood Cancer 2006: 47: 200-205. (Pubitemid 44025253)
13. Wagner HJ, Jabs W, Smets F, et al., Realtime polymerase chain reaction (RQ-PCR) for the monitoring of Epstein-Barr virus (EBV) load in peripheral blood mononuclear cells. Klin Padiatr 2000: 212: 206-210. (Pubitemid 30650556)
14. Bordon V, Bravo S, Van Renterghem L, et al., Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: Incidence and outcome of CMV infection and disease. Transpl Infect Dis 2008: 10: 19-23. (Pubitemid 351171316)
15. Brunstein CL, Weisdorf DJ, Defor T, et al., Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006: 108: 2874-2880.
16. Juvonen E, Aalto S, Tarkkanen J, Volin L, Hedman K, Ruutu T,. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007: 92: 819-825. (Pubitemid 350155308)
17. Cohen J, Gandhi M, Naik P, et al., Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005: 129: 229-239. (Pubitemid 40562444)
18. Landgren O, Gilbert ES, Rizzo JD, et al., Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009: 113: 4992-5001.
19. Micallef INM, Chhanabhai M, Gascoyne RD, et al., Lymphoproliferative disorders following allogeneic bone marrow transplantation: The Vancouver experience. Bone Marrow Transplant 1999: 23: 629-630.
20. Hicks LK, Woods A, Buckstein R, et al., Rituximab purging and maintenance combined with auto-SCT: Long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009: 43: 701-708.
21. Cooper N, Davies EG, Thrasher AJ,. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009: 146: 120-122.
22. Dunleavy K, Hakim F, Kim HK, et al., B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005: 106: 795-802. (Pubitemid 41076417)
23. Masjosthusmann K, Ehlert K, Eing BR, et al., Delay in B-lymphocyte recovery and function following rituximab for EBV associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant 2009: 43: 679-684.
24. Heslop H,. How I treat EBV lymphoproliferation. Blood, 2009: 114: 4002-4008.